The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics
Open accessAbstract
The biological roles of the matrix metalloproteinases (MMPs) have been traditionally associated with the degradation and turnover of most of the components of the extracellular matrix (ECM). This functional misconception has been used for years to explain the involvement of the MMP family in developmental processes, cell homeostasis and disease, and led to clinical trials of MMP inhibitors for the treatment of cancer that failed to meet their endpoints and cast a shadow on MMPs as druggable targets. Accumulated evidence from a great variety of post-trial MMP degradomics studies, ranging from transgenic models to recent state-of-the-art proteomics screens, is changing the dogma about MMP functions. MMPs regulate cell behavior through finely tuned and tightly controlled proteolytic processing of a large variety of signaling molecules that can also have beneficial effects in disease resolution. Moreover, net proteolytic activity relies upon direct interactions between the different protease and protease inhibitor families, interconnected in a complex protease web, with MMPs acting as key nodal components. Such complexity renders simple interpretation of Mmp knockout mice very difficult. Indeed, the phenotype of these models reveals the response of a complex system to the loss of one protease rather than necessarily a direct effect of the lack of functional activity of a protease. Such a shift in the MMP functional paradigm, together with the difficulties associated with current methods of studying proteases this highlights the need for new high content degradomics approaches to uncover and annotate MMP activities in vivo and identify novel interactions within the protease web. Integration of these techniques with specifically designed animal models for final validation should lay the foundations for the development of new inhibitors that specifically target disease-related MMPs and/or their upstream effectors that cause deleterious effects in disease, while sparing MMP functions that are protective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–223 of 223
Sumitomo, K., Kurisaki, A., Yamakawa, N., Tsuchida, K., Shimizu, E., Sone, S., & Sugino, H. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00407-9 · Cited by 74
Tayebjee, M. H., Lip, G. Y. H., & MacFadyen, R. J. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053507270 · Cited by 73
Emonard, H., Bellon, G., de Diesbach, P., Mettlen, M., Hornebeck, W., & Courtoy, P. J. (2004) · Biochimie · doi:10.1016/j.biochi.2004.11.013 · Cited by 72
Fowlkes, J. L., Serra, D. M., Bunn, R. C., Thrailkill, K. M., Enghild, J. J., & Nagase, H. (2003) · Endocrinology · doi:10.1210/en.2003-0636 · Cited by 69
Nisato, R. E., Hossein, G., Sirrenberg, C., Butler, G. S., Crabbe, T., Docherty, A., Wiesner, M., Murphy, G., Overall, C. M., Goodman, S. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1512 · Cited by 68
Self-citationBlobel, C. (2002) · Inflammation Research · doi:10.1007/bf02684007 · Cited by 66
Cell-Surface-Associated Tissue Transglutaminase Is a Target of MMP-2 Proteolysis
Belkin, A. M., Zemskov, E. A., Hang, J., Akimov, S., Sikora, S., & Strongin, A. Y. (2004) · Biochemistry · doi:10.1021/bi049266z · Cited by 61
Ichikawa, Y., Ishikawa, T., Momiyama, N., et al. (2006) · Oncology Reports · doi:10.3892/or.15.2.311 · Cited by 61
Activation of Transforming Growth Factor β in Chondrocytes Undergoing Endochondral Ossification
D’Angelo, M., Sarment, D. P., Billings, P. C., & Pacifici, M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2339 · Cited by 61
Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)
LIJNEN, H. R., Arza, B., HOEF, B. V., Collen, D., & Declerck, P. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006475200 · Cited by 58
Matrix metalloproteinases target protease-activated receptors on the tumor cell surface
Pei, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.011 · Cited by 55
Apolipoprotein C-II is a novel substrate for matrix metalloproteinases
Kim, S. Y., Park, S. M., & Lee, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.182 · Cited by 53
MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing
Lehti, K., Rose, N. F., Valavaara, S., Weiss, S. J., & Keski-Oja, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.035279 · Cited by 52
MMPs Are IGFBP‐Degrading Proteinases: Implications for Cell Proliferation and Tissue Growth
Fowlkes, J. L., SERRA, D. M., Nagase, H., & Thrailkill, K. M. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07765.x · Cited by 49
Cunningham, A. C., Hasty, K. A., Enghild, J. J., et al. (2002) · Biochemical Journal · doi:10.1042/bj20020696 · Cited by 48
Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter
Overall, C. M. (2004) · Biochemical Journal · doi:10.1042/bj20041433 · Cited by 45
Self-citationPlasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Hasina, R., Hulett, K., Bicciato, S., Bello, C. D., Petruzzelli, G. J., & Lingen, M. W. (2003) · PubMed · Cited by 44
MT1-MMP Down-regulates the Glucose 6-Phosphate Transporter Expression in Marrow Stromal Cells
Currie, J.-C., Fortier, S., Sina, A., Galipeau, J., Cao, J. P., & Annabi, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610894200 · Cited by 36
Bellehumeur, C., Collette, T., Maheux, R., Mailloux, J. R., Villeneuve, M., & Akoum, A. (2005) · Human Reproduction · doi:10.1093/humrep/deh749 · Cited by 35
Inactivation of the serpin α2-antiplasmin by stromelysin-1
LIJNEN, H. R., HOEF, B. V., & Collen, D. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00186-8 · Cited by 33
Functional genetic mouse models: promising tools for investigation of the proteolytic internet
Krüger, A. (2008) · Biological Chemistry · doi:10.1515/bc.2009.015 · Cited by 28
Kopitz, C., Gerg, M., Gänsbacher, B., & Krüger, A. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.078 · Cited by 9
Blavier, L., & DeClerck, Y. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.024 · Cited by 4
Cited by
Extracellular matrix structure
Theocharis, A. D., Skandalis, S. S., Gialeli, C., & Karamanos, N. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.001 · Cited by 2,598
“To start, metalloproteases produced by several cell types such as fibroblasts, epithelial, endothelial inflammatory and cancer cells are responsible for the catabolism of almost all ECM molecules [286], as well as non-ECM cell regulators [287, 288].”
BackgroundBiological role of matrix metalloproteinases: a critical balance
Löffek, S., Schilling, O., & Franzke, C.-W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00146510 · Cited by 756
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Pathophysiology of the brain extracellular matrix: a new target for remyelination
Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S., & Yong, V. W. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3550 · Cited by 549
Bauvois, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.001 · Cited by 543
Metadata
- Authors
- Rodríguez, D., Morrison, C. J., & Overall, C. M.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 1803
- Issue
- 1
- Pages
- 39-54
- ISSN
- 0167-4889 (ISSN-L)
- OpenAlex
- W2004540849
- Cited by
- 560
- References
- 223
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.